Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05483400 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Study acronym: TIRACAN
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2022 to Oct 18, 2023 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2022 to Oct 18, 2023
    • Study sites: 0 to 1
  3. Start date: Sep 2022 to Dec 2022v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
Trial Details
NCT Number NCT05483400
Lead Sponsor University Medical Center Groningen
Conditions Head and Neck Neoplasms, MSI-H Cancer, Melanoma
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov